Evidence map›Paper›PMID 40607407›Full record

ArticleFrontiers in immunology2025

Landscape analysis of matrix metalloproteinases reveals key prognostic markers for prostate cancer.

Wei Li, Xi Wei, Ying Yu, Yuan Tian, Qi Yu, Jun Qiao, Yuewei Tao, Yanfeng Li, Tao Li

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei Li *Department of Urology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Xi Wei *Department of Urology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Ying Yu *Zhejiang Provincial People's Hospital Bijie Hospital, Bijie, China.
Yuan TianDepartment of Urology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Qi YuDepartment of Urology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Jun QiaoDepartment of Urology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Yuewei TaoSchool of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.
Yanfeng LiDepartment of Urology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Tao LiDepartment of Urology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer (PCa) is the most common male malignancy and significantly impairs patient's survival. Matrix metalloproteinases (MMPs) play a crucial role in tumor progression, yet the comprehensive role of MMPs in PCa remains unclear. Method: Data from UCSC and GEO databases were firstly analyzed to evaluate expression characteristics, prognostic value, immune-cell infiltration, tumor-mutation burden (TMB), microsatellite-instability (MSI), immunotherapy sensitivity, and drug sensitivity in PCa. COX-regression analysis was utilized to identify MMPs that affected (Disease-free survival) DFS. Various cellular functional experiments and conditional medium cultivation system were utilized to verify the effect of MMP11 on PCa cells. Subsequently, single-cell transcriptome and spatial-transcriptome data was analyzed to explore the regulatory effect of MMP11 on microenvironment. Result: Most MMPs exhibit differential expression between tumor and normal tissues, with specific MMPs correlating with pathological features of PCa. Among 24 MMPs analyzed, MMP11 was uniquely associated with shorter DFS. High MMP11 expression correlated with increased infiltration of regulatory Tregs and M2 macrophages, elevated immune checkpoint molecule expression, higher TMB, MSI, and enhanced immunotherapy sensitivity. MMP11 suppression inhibited PCa cell proliferation, migration, invasion, and epithelial-mesenchymal transition.MMP11 was predominantly expressed in fibroblasts and linked to the establishment of an immunosuppressive tumor microenvironment. Targeting MMP11 in cancer-associated fibroblasts reversed their pro-tumorigenic effects on PCa progression. Finally, MMP11 is broadly upregulated across malignancies and associated with poor prognosis in multiple cancer types. Conclusion: This study comprehensively explored the role of MMPs in PCa. Noteworthy, we further proved that MMP11 significantly promoted PCa probably through reprogramming of tumor microenvironment, which might provide a promising-target for PCa treatment.

Indexed as

Biomarkers, TumorMatrix Metalloproteinase 11Matrix MetalloproteinasesProstatic NeoplasmsCell Line, TumorGene Expression Regulation, NeoplasticHumansMalePrognosisTumor MicroenvironmentBiomarkers, TumorMatrix Metalloproteinase 11Matrix MetalloproteinasesMMP11 protein, humanfibroblastsimmune microenvironmentmatrix metalloproteinasesMMP11prostate cancer

Identifiers

PMID40607407
PMCPMC12213759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.